Home › Multiple Myeloma › Minnesota › Rochester
Pag-aaral pangklinika para sa Multiple Myeloma sa Rochester, MN
24 pag-aaral para sa Multiple Myeloma ang naghahanap ng mga kalahok sa mga site sa loob at paligid ng Rochester (sa loob ng humigit-kumulang 30 milya). Buksan ang pag-aaral upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
SMS-Based Remote Symptom Monitoring for Patients With Plasma Cell Disorders
Nagre-recruitObservasyonal na pag-aaral
- Mayo Clinic in Rochester, Rochester
A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM)
Nagre-recruitPhase 3
- Mayo Clinic, Rochester
A Study Comparing JNJ-79635322 and an Anti-B-cell Maturation Antigen (BCMA)xCD3 Bispecific Antibody in Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 3
- Mayo Clinic Rochester, Rochester
A Study Comparing JNJ-79635322 and Teclistamab in Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 3
- Mayo Clinic, Rochester
A Long-term Study for Participants Previously Treated With Ciltacabtagene Autoleucel
Nagre-recruitPhase 4
- Mayo Clinic Rochester, Rochester
Testing Teclistamab (TECVAYLI) in Combination With Iberdomide for Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 1
- Mayo Clinic in Rochester, Rochester
A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant
Nagre-recruitPhase 2/3
- Mayo Clinic Hospital Rochester /ID# 277886, Rochester
Study of Arlocabtagene Autoleucel (BMS-986393) a GPRC5D-directed CAR T Cell Therapy in Adult Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 2
- Mayo Clinic in Rochester, Minnesota, Rochester
Study of SIM0500 Alone in Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 1
- Mayo Clinic Rochester, Rochester
Dasatinib and Quercetin With CAR-T Therapy for the Treatment of Patients With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 2
- Mayo Clinic in Rochester, Rochester
Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial
Nagre-recruitPhase 3
- Mayo Clinic in Rochester, Rochester
A Study of an MMSET Inhibitor in Patients With Relapsed and Refractory Multiple Myeloma
Nagre-recruitPhase 1
- Mayo Clinic - Transplant Center - Rochester, Rochester
AZD0120 in Relapsed/Refractory Multiple Myeloma (DURGA-1)
Nagre-recruitPhase 1/2
- Research Site, Rochester
Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)
Nagre-recruit
- Mayo Clinic in Rochester, Rochester
A Study to Evaluate the Efficacy of Cemsidomide + Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma
Nagre-recruitPhase 2
- Mayo Clinic - Minnesota, Rochester
A Study to Evaluate the Safety, Effectiveness and Tolerable Dose of Arlocabtagene Autoleucel (BMS-986393) in Novel Combinations in Participants With Relapsed and/or Refractory Multiple Myeloma
Nagre-recruitPhase 1
- Mayo Clinic in Rochester, Minnesota, Rochester
A Study to Assess Adverse Events of Intravenously (IV) Infused Etentamig (ABBV-383) in Adult Participants With Relapsed or Refractory Multiple Myeloma
Nagre-recruitPhase 1
- Mayo Clinic - Rochester /ID# 251164, Rochester
A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments
Nagre-recruitPhase 1
- Mayo Clinic, Rochester
Elotuzumab, Daratumumab, Iberdomide, and Dexamethasone for the Treatment of Relapsed Multiple Myeloma
Nagre-recruitPhase 1/2
- Mayo Clinic in Rochester, Rochester
Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment
Nagre-recruitPhase 3
- Mayo Clinic in Rochester, Rochester
A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma
Nagre-recruitPhase 1
- Mayo Clinic in Rochester, Rochester
Remote Monitoring With Health-Coaching to Improve Quality of Life in Older Patients With Multiple Myeloma
Nagre-recruit
- Mayo Clinic in Rochester, Rochester
cfDNA Assay Prospective Observational Validation for Early Cancer Detection and Minimal Residual Disease
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- Mayo Clinic, Rochester
Family Study of Lymphoproliferative Disorders
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- Mayo Clinic, Rochester
Pag-aaral para sa Multiple Myeloma sa ibang lungsod
- New York City, NY60 pag-aaral
- Boston, MA42 pag-aaral
- Atlanta, GA41 pag-aaral
- Houston, TX38 pag-aaral
- Durham, NC37 pag-aaral
- Nashville, TN32 pag-aaral
- Denver, CO26 pag-aaral
- Columbus, OH24 pag-aaral
- Baldwin Park, CA23 pag-aaral
- St. Louis, MO23 pag-aaral
- Chicago, IL22 pag-aaral
- Washington, DC22 pag-aaral
Iba pang pag-aaral sa Rochester
- Kanser sa Suso42 pag-aaral
- Non-Small Cell Lung Cancer37 pag-aaral
- Kanser (lahat ng uri)30 pag-aaral
- Metastatic Cancer30 pag-aaral
- Kanser sa Ovary29 pag-aaral
- Colorectal Cancer29 pag-aaral
- Kanser sa Pancreas23 pag-aaral
- Pagkabigo ng Puso22 pag-aaral
- Kanser sa Prostate22 pag-aaral
- Kanser sa Baga20 pag-aaral
- Kanser ng Endometrium19 pag-aaral
- Chronic Lymphocytic Leukemia19 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 1, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.